Cutler Group’s Enveric Biosciences ENVB Stock Holding History

Cutler Group’s Portfolio ENVB Stock Details ENVB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-1	Closed	-$1K	–	5046
2022 Q2	$1K	Hold	1	–	–	﹤0.01%	4552
2022 Q1	$1K	Hold	1	–	–	﹤0.01%	4939
2021 Q4	$5K	Hold	1	–	–	﹤0.01%	4170
2021 Q3	$12K	Buy	+1	New	+$19.4K	﹤0.01%	3755

Other funds holding ENVB

AdvisorShares Investments Bethesda, Maryland $549M AUM 32.58% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Cutler Group's ENVB Position: Q3 2022 in Review

Cutler Group sold out of Enveric Biosciences (ENVB) in Q3 2022, closing a stake of 1 share — an estimated $1K sold.

Cutler Group first reported a position in ENVB in Q3 2021 and held it in 4 quarters. The position peaked at $12K in Q3 2021. 9 funds tracked by Wall St. Rank hold ENVB as of Q3 2022.

Cutler Group reported no remaining Enveric Biosciences position as of Q3 2022 after selling out during the quarter.
Cutler Group sold 1 Enveric Biosciences share in Q3 2022, an estimated $1K.
Cutler Group first reported a position in Enveric Biosciences in Q3 2021 and held it in 4 quarters.
Cutler Group's Enveric Biosciences position peaked at $12K in Q3 2021.
9 funds tracked by Wall St. Rank held Enveric Biosciences as of Q3 2022.

Based on Cutler Group's 13F filing for Q3 2022, filed 25 Oct 2022.